Revelation Biosciences Inc. has entered into an exclusive worldwide license agreement with Vanderbilt University to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD) for treating or preventing infections.
Virtici LLC has been granted a Small Business Innovation Research (SBIR) award by the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) to advance VTC-886, a first-in-class small molecule for the prevention of Porphyromonas gingivalis infection.
Intravacc BV has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG), the cause of the sexually transmitted disease gonorrhea.
Researchers from Enanta Pharmaceuticals Inc. presented preclinical data for the small molecule non-nucleoside respiratory syncytial virus (RSV) L-protein inhibitor, EDP-323, being developed for the treatment of RSV infection.
Infex Therapeutics Ltd. has divulged nonstructural protein 3 (nsp3, PL-PRO) macrodomain (Mac1) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Imunon Inc. has reported partial results from an ongoing nonhuman primate study designed to examine the immunogenicity of its proprietary Placcine vaccine (PL-COV). The data support Placcine as a viable alternative to mRNA vaccines.
Researchers from the University of Queensland have published preclinical data on the novel glycopeptide antibiotic MCC-5145, being developed for the treatment of gram-positive bacterial infections.
Antimicrobial peptides (AMPs) are a type of active peptide produced by the organism that are important host-defense factors, with broad-spectrum antibacterial properties, as well as significant properties such as antifungal and antiviral activity and immune regulation, among others.
Preclinical research led by the University Hospital Würzburg in Germany shows early promise for chimeric antigen receptor (CAR) T-cell therapies to treat invasive pulmonary aspergillosis, a serious fungal infection with limited current treatment options.
RSS
